Scarica l'app Stockscreener
105.81
0.02%
0.02
Pre-mercato:
106.31
0.50
+0.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
How The Mirum Pharmaceuticals (MIRM) Story Is Evolving With New Analyst Targets And Trial Milestones - Yahoo Finance
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets - Sahm
Mirum Pharmaceuticals rally reflects confidence in late-stage liver disease assets - MSN
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Mirum Pharmaceuticals stock hits all-time high at 109.29 USD By Investing.com - Investing.com Australia
Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach - TechStock²
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
MIRM Stock Jumps As HDV Data Fuel Bullish Targets - timothysykes.com
Mirum Pharmaceuticals stock surges 12% on trial results By Investing.com - Investing.com Canada
Mirum Pharma - TradingView
MIRM: Volixibat met its primary endpoint in PSC, showing robust itch reduction and strong safety - TradingView
Mirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs Placebo - Yahoo Finance
MIRM Stock Jumps As HDV Data Sends Analysts Scrambling Higher - StocksToTrade
Up to BAT in PSC, Mirum base case proven with phase IIb - BioWorld News
Mirum Pharmaceuticals stock hits all-time high at 109.29 USD - Investing.com
Mirum Pharmaceuticals Reports Positive Volixibat Phase 3 Results for Cholestatic Pruritus in PSC – Efficacy and Safety Data Released - Minichart
Mirum’s volixibat meets primary endpoint in PSC pruritus trial - Investing.com UK
Baird reiterates Mirum Pharmaceuticals stock rating on positive trial data By Investing.com - Investing.com Canada
MIRM: Volixibat met its Phase 2b endpoint, significantly reducing pruritus in PSC patients - TradingView
MIRM: Volixibat significantly reduced pruritus in PSC patients, meeting the VISTAS Phase 2b primary endpoint - TradingView
MIRM: Volixibat and brelovitug achieved key efficacy and safety milestones in PSC and HDV Phase 2b trials - TradingView
Mirum’s Volixibat Succeeds in Phase 2b PSC Itch Trial - TipRanks
Mirum’s volixibat meets primary endpoint in PSC pruritus trial By Investing.com - Investing.com Canada
Mirum Pharmaceuticals' Volixibat Meets Primary Endpoint in VISTAS Phase 2b for PSC Itch - TradingView
Volixibat eases cholestatic itch in PSC trial for Mirum (NASDAQ: MIRM) - Stock Titan
Mirum Pharmaceuticals Announces Primary Endpoint Met In VISTAS Study Of Volixibat In Patients With Primary Sclerosing Cholangitis - marketscreener.com
Mirum Pharmaceuticals to Host Investor Call to Share Topline Resu - The National Law Review
Mirum Pharmaceuticals to Announce Volixibat Primary Sclerosing Cholangitis VISTAS Study Results on May 4, 2026 - geneonline.com
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 | FinancialContent - FinancialContent
How (MIRM) Movements Inform Risk Allocation Models - Stock Traders Daily
Earnings Preview: MIRM to Report Financial Results Post-market on May 06 - Moomoo
Pictet Asset Management Holding SA Purchases 35,997 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - BioSpace
Mirum Pharmaceuticals, Inc. (MIRM) expected to beat earnings estimates: What to know ahead of Q1 release - MSN
All eyes on Mirum Pharmaceuticals earnings ahead of PSC trial data - Investing.com Australia
All eyes on Mirum Pharmaceuticals earnings ahead of PSC trial data By Investing.com - Investing.com India
Evercore Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $126 - Moomoo
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00 at Stifel Nicolaus - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance Singapore
Stifel Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $130 - Moomoo
HC Wainwright Has Pessimistic Outlook of MIRM Q1 Earnings - MarketBeat
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Shareholder Returns And Rare Disease Pipeline Progress - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Mirum Pharmaceuticals (MIRM) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
MIRM Stock Price, Quote & Chart | MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) - ChartMill
Mirum HDV Trial Success Adds New Late Stage Growth Option - Yahoo Finance
Stifel raises Mirum Pharmaceuticals price target on pipeline outlook By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $112.00 at Robert W. Baird - MarketBeat
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus - BioSpace
Mirum’s hepatitis delta drug meets phase 2b study goals - Investing.com UK
BlackRock (NASDAQ: MIRM) Holds 3.47M Shares, 5.7% Stake - Stock Titan
Mirum’s brelovitug succeeds in Phase 2b HDV trial - TipRanks
Baird raises Mirum Pharmaceuticals stock price target on HDV data By Investing.com - Investing.com Canada
Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright - TipRanks
Mirum Pharmaceuticals Reports Positive Phase 2b Results for Brelovitug in HDV – Key Efficacy and Safety Data Shared, Phase 3 and BLA Timeline Announced - Minichart
Mirum Pharmaceuticals Announces Primary Endpoint Met In Phase 2B Portion Of The Azure-1 Study - TradingView
Mirum’s hepatitis delta drug meets phase 2b study goals By Investing.com - Investing.com South Africa
Brelovitug shows high HDV response rates in Mirum (NASDAQ: MIRM) Phase 2b - Stock Titan
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):